Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
[url=http://finance.yahoo.com/news/vinergy-resources-mj-biopharma-acquire-130000221.html]http://finance.yahoo.com/news/vinergy-resources-mj-biopharma-acquire-130000221.html[/url]
Vinergy Resources/MJ BioPharma to Acquire 65% of Health Canada and FDA Licensed Laboratory to Pursue Drug Testing and Dosage of CBDs, THC and Terpenes
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb 22, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes it has signed a binding Letter of Intent ("LOI") to acquire 65% of Biolennia Laboratories Inc. (the "Laboratory").
Biolennia will provide a host of drug testing services to support MJ BioPharma's product line and provide research and development (R&D), product formulation, extraction facilities, systems design and develop standard-operating-procedures (SOPs).
The lab is currently in the process of applying for a Dealer's License from Health Canada. Once issued the license will allow the Company to process cultivated cannabis (extracts and/or derivatives) for R&D purposes.
Biolennia was founded in 2001 by Dean Swift as the internal R&D and quality testing laboratory to support Micrylium Laboratories Inc. ("Micrylium"). In 2002 it upgraded to a full active ingredient and microbial testing laboratory for several Health Canada approved products. Biolennia is a specialty development laboratory with expertise in Microbiology (bacteria, fungi, viruses), Chemistry (proteins, enzymes, drug testing, material science and analytics). The Laboratory currently provides testing, R&D and quality control for a proprietary line of Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrlylium.
Biolennia has in-house expertise in methods accepted by Health Canada and the Federal Drug Administration (FDA) for determining purity and quality of many of the materials and methods used in validating cannabis and or testing cannabis products. Biolennia brings a highly talented team of Microbiologists who are familiar with testing high purity water, ethanol, ethyl acetate, propylene glycol, xylitol, glycerine, propandiaol, d-limonene, myrcene, and beta caryophelline.
The lab operates from a secure premises in Toronto, Ontario (Canada) alongside Micrylium which manufactures products registered under licensure from various agencies including: CE, FDA, EPA, Health Canada, Swiss BAG, and German VAH. MJ BioPharma will provide the proprietary line of disinfectant products, globally to the cannabis industry to ensure improved hygiene for cultivation facilities, nutrient hoses, labs, extraction systems, dry utensils and edibles manufacturing spaces.
Under the terms of the acquisition Vinergy/MJ BioPharma will acquire 65% of Biolennia for CAD $260,000 and 150,000 shares of Vinergy at the time the definitive agreement is signed. The Company expects to close on the acquisition in Q1-2017.
"This is a fantastic acquisition for us and supports our entire product line and R&D initiatives moving forward. Our technical expertise in drug testing, extractions, and formulas containing CBD, Terpene, THC and other botanicals is continually being furthered. We have a remarkable team. We feel strongly that science based products formulated from extracts and derivatives that are properly dosed and manufactured in GMP environments to ensure consistency and safety for all customers whether they be recreational or medical users, is the future of the cannabis industry," MJ BioPharma CEO Kent A. Deuters.
European Acquisition Update
Based on early due diligence the Company has terminated its letter of intent announced February 02, 2017 to acquire up to 51% a European plant breeder.
Fundamental CASH COW
Reliq is a future cash cow, and i should even say cash cows. The news today represents just 1 agreement, let us not forget Reliq currently has 4 other ongoing pilots...
- Sacred Heart is a member of the very large Ascension Health. With 2,500 sites of care in 24 states and the District of Columbia, Ascension Health is the US’s largest non-profit health system and the world’s largest Catholic health system.
- The National Health Service (NHS) is the publicly funded healthcare system for England and it is the largest and the oldest single-payer healthcare system in the world.
- The Feldman Institute in Louisiana is an interventional pain management clinic and surgical center, and is considered to be a regional center that serves a large group of patients within Louisiana and its surroundings.
- Hamilton Health Sciences (HHS) is a family of seven unique hospitals, a cancer centre and an urgent care centre, serving more than 2.3 million residents of Hamilton and south central Ontario, Canada. HHS is the second largest hospital group in Ontario.
Now...just this 1 agreement with Paz home health represents a ANNUAL RECURRING REVENUES of +6M USD
And that represents only 40% of the potential clients on just this 1 deal.
Do the numbers using market multiples on revenue.....$80 Million,,,,
Now imagine if they lock in the other 4 ongoing pilots,,,,,
We are talking about MASSIVE numbers,,,
One day investors will be running after RHT shares....and times flies..
Yep this guy worked with Aurora !
Joel Fuzat, facility director at Aurora 'recommended' him, saying "John Simon's knowledge, energy, enthusiasm, and ability to make technical regulatory processes transparent is invaluable."
https://www.linkedin.com/in/johnsimon5559/
Another great article by Chris Parry
Vinergy Resources (VIN.C) announces weed-strip tech breakthrough
You’ve got to give credit to Vinergy Resources (VIN.C), AKA MJ Biopharma, they said they were going to have plenty of news over the coming months, and they’ve definitely delivered.
Today’s news? The company boasts of:
“..a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body.”
And:
“This unique approach forms the basis for a fundamentally new technology and product category. The technology is called “BURST” due to its incredibly fast action and ability to enhance the body’s absorption of various medicinal ingredients contained in the Company’s products. The BURST system is built on natural botanical polymers delivering specially processed high purity cannabinoid complexes. The unique system for cannabinoid activation maintains the natural balance of THC, CBD, CBN and terpenes while preserving the maximum therapeutic effect and potentially delivering it to the body faster than any currently available delivery method. The patent pending technology allows for a more complete palatable drug delivery system that is effective and enhances the patient or user experience while intensifying flavour.
And if that makes sense to you, congratulations on your PhD. Here’s the layman’s version:
VIN’s pointy-heads have been working on ‘breath strip’ delivery platforms for weed, which companies such as Lifestyle Delivery Systems (LDS.C) have also been cracking on with.
The problem with strips as a delivery system is the good stuff (THC, CBDs) tends to congeal, meaning you might get a bunch of THC on one corner of the strip and nothing on the other side. Both VIN and LDS say they have a solution to this – I’ve heard both described, and they’re not the same.
You kind of want the effect of the strip to be as immediate as possible, otherwise you get the ‘gummy bear effect’, where someone takes one, has no reaction after ten minutes, then takes another four, and spends the next eight hours complaining that their face is covered in ants.
Vinergy’s new tech, they claim, will make the strip work better, be faster absorbed into the body, and in a way that will intensify flavour.
Now, it’s one thing to claim such a thing exists. It’s another to deliver it in a form that is market-ready.
Vinergy’s origins come from a long successful family business that specifically does this kind of work, creating formulations for pharma companies, so they’re perfectly placed to not only deliver on these promises, but get them to market in a way that’s good for cannabis delivery, but also other pharma needs.
What’s also important is not just that the nutrients get into the body, but that they all get into it at the same time, because they work together. The VIN ‘BURST’ tech is claimed to do just that.
Whatever is happening at the pointy end of the Vinergy labs, the share price shows the market is really liking what they’re up to. In mid-December, this was a $0.23 stock, fresh off the boat. Today, two months later, holders are sitting on a three-bagger.
And the story is just warming up.
— Chris Parry
Key words here are licensing and partnering. So who will it be....Canopy, Aurora, Aphria, Emblem etc..... This is why we buy today.
MJ Biopharma is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad
Biotech Breakthroughs Utilizing R & D
Countries across the globe continue to legalize cannabis and it is only a matter of time until the U.S. gets on the bandwagon.
The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.
A Stock to Watch
Today, Vinergy Resources (VIN: CSE) (VNNYF: OTCQB) reported a breakthrough while conducting R&D on its oral cannabinoid (CBD) delivery strips and controlled time release capsule technology.
We highlighted VIN.CN as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase. MJ Biopharma is a private cannabis technology company focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused juices, teas, coffee and extract drinks, as well as the development of pharmaceutical grade delivery systems.
MJ Biopharma is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad. The company said that the novel approach that is under development will become the basis for new products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of CBD in the body.
Opportunity to Create a New Product Category
This unique approach forms the basis for a fundamentally new technology and possible new product category. The technology is called BURST due to the speed at which it can enhance the body’s absorption of various ingredients. The BURST system is built on natural botanical polymers delivering specialty processed high purity cannabinoids.
MJBiopharma CEO Kent Deuters said, “This is a great breakthrough for us and the product line we have planned. The technology can also be utilized in our time release capsules which of course will have a slower absorption rate. We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural drug as a way to reduce side effects, reduce drug costs and just feel better all around.”
You think this is another GWPH in the making? They're trading in the $120 range.
Well I think AXIM for starts (600 million market cap).
We shoudl at minimum be at 100m market cap, yet we are still 30....
But C.Parry called us teh GWPH in the making
https://equity.guru/2017/01/18/vinergy-resourcesmj-biopharma-vin-c-ramps-up-to-clinical-testing-of-cbd-therapeutics/
''The GW Pharma-in-the-making announced Wednesday it had signed Dr. William Panenka, MD, as the Chair of its Scientific Advisory Board, a move that establishes the credentials of the company in chasing a Big Pharma future for its products.''
This is massive news, CBD Strips are the way of the future my friends. Exciting morning to say the least.
Yes but I love the time release capsules. And most importantly all other companies trying to do this use oil (bad taste bad delivery system.
VNNYF is using water and saliva !!
''water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body.
This unique approach forms the basis for a fundamentally new technology and product category. ''
''The technology can also be utilized in our time release capsules which of course will have a slower absorption rate. We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural product as a way to reduce side effects and drug,”
Now watch as I expect majors (LP's) want to partner with VNNYF not only for product technology AND products but also for territory !!
Major Breakthroughs Made In Cannabinoid Delivery
VNNYF (market cap 34 million) vs AXIM (market cap 600 million)
Look at AXIM Biotechologies, go look at chart back in Oct lol....
Oct 24tgh 2016 AXIM was trading at 40 cents....3 montsh later Jan 12th 2017, $19.80
They are in the cannabinoid delivery system (As is VNNYF)...
AXIM 700 Million market cap, They make no money and have no money:
Earning a current market cap value of $772M, AXIM has $870k in cash on the books, which stands against about $4.1M total current liabilities. AXIM is effectively pre-revenue at this point.
About AXIM
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products.
AXIM Biotechnologies Inc. has made a name for itself by creating unique delivery systems for cannabinoids
VIN’s goal is to control every step of the production process, from genetics, right through to extraction, ensuring only the highest quality extracts are used in the formulation of their products (strips, time release capsules and other products currently under development for the medical and recreational cannabis space)
a) BioMED (Extract Oils, Time Release Capsules, Vaporizer Delivery Systems)
b) BioLIFE (Pharmaceutical grade delivery systems, Nutraceutical and Medicinal Health Products)
c) BioEDIBLES (Manufactured Breath Strips and Infused Food Products)
d) BioDRINKS (Infused Juices, Teas, Coffee, Extract Drinks)
This is HUGE... I once said this was another AXIM, but AXIM has 1 product, gum. VNNYF will have many products. And we use C02, not oil !!
[url]
http://www.cbj.ca/vinergy-resourcesmj-biopharma-announces-breakthrough-in-oral-cannabinoid-strip-and-time-release-capsule-technologies/[/url][tag]VINERGY RESOURCES/MJ BIOPHARMA ANNOUNCES BREAKTHROUGH IN ORAL CANNABINOID STRIP AND TIME RELEASE CAPSULE TECHNOLOGIES[/tag]
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Feb. 14, 2017) - Vinergy Resources Ltd. (“Vinergy” or the “Company”)(CSE:VIN)(CSE:VIN.CN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body.
This unique approach forms the basis for a fundamentally new technology and product category. The technology is called “BURST” due to its incredibly fast action and ability to enhance the body’s absorption of various medicinal ingredients contained in the Company’s products. The BURST system is built on natural botanical polymers delivering specially processed high purity cannabinoid complexes.
The unique system for cannabinoid activation maintains the natural balance of THC, CBD, CBN and terpenes while preserving the maximum therapeutic effect and potentially delivering it to the body faster than any currently available delivery method.
The patent pending technology allows for a more complete palatable drug delivery system that is effective and enhances the patient or user experience while intensifying flavour.
“This is a great breakthrough for us and the product line we have planned. The technology can also be utilized in our time release capsules which of course will have a slower absorption rate.
We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural product as a way to reduce side effects and drug,” said Mr. Kent Deuters, CEO of MJ Biopharma. “We look forward to providing additional updates in the coming weeks,” added Mr. Deuters.
The Hemp Business Journal estimates the total U.S. CBD market will grow to $2.1 billion in consumer sales by 2020.
Bottoms's in, traders out ! Up we go !
Follow me on twitter @CUUVETTE350
Read this article Canopy Growth is trying to enter Europe market..
German cannabis market could be significant for Canopy Growth Corp,
perefct synergy with $VNNYF
https://equity.guru/2017/02/02/vinergy-resources-vin-c-buys-their-own-green-organic-dutchman-kinda/
The company they’re buying into has an FDA-certified laboratory with an R&D facility, rooting station, and weening facilities in in addition to a low cost, high efficiency lab. The target’s plan is to make a global push into the tissue culturing industry
The marijuana push within the company comes with an existing cannabis license, an export license, and strong interest from the growing EU market for cannabis and CBDs. Money from the sale to Vinergy will reportedly go towards building out that aspect of the business and accelerating the cannabis product development side.
Rebound !! Take advantage of the dips !
(RTI did the same thing. )
RTI is 77m market cap right now...VNNYF is only 34
VNNYF needs to double and we're still undervalued
Shares are getting gobbled up here...
It doesn't suck, you can buy more cheaper !! This is the time. This will be a $3 stock
Biotech Is Booming
Great Article and bolds well for VNNYF as its being called the GW Pharma in the making !!
Smart money accumulating...
Great volume today, another nice breather/consolidation day before we start moving into $1.50 territory, then $2 - $2.50 is next.
It's been like this since the mid 20's...
We should be at $4 based on the most recent deal...
20x ($14m x 51%) = $140 million = $3.88
25x (14m x 51%) = $178 million = $4.44
Don't forget what we have :
* Access to an extensive catalogue of over 2000 hemp and cannabis strains
Hmm I wonder what they plan to do with these IP 2000 strains ? Oh yeah..they said it in last NR:
''The Company will aim to work with large growers and provide access for them to a comprehensive catalogue of cannabis strains. ''
Work with large growers ? Hmmmm what else... Oh yes I forgot last paragraph of 1st NR:
* MJ Biopharma's expertise lies in its extracts and custom formulations. The company will also aim to in- license and joint venture on best in class technologies and products for both the medicinal and recreational markets - domestically and internationally.
What else do we have ?
* FDA-certified laboratory
* R&D facility
* Rooting station
* Weening facilities
* Low cost, high efficiency lab.
* Existing cannabis license
* An export license
Don't forget the plan:
VIN (MJ BIOPHARMA) PLAN:
* Expand rapidly into the hemp, cannabis and cannabinoid (CBD) sectors across Europe.
* Utilize our first mover advantage to take a leading market position in multiple countries
* "Given the current marketplace dynamics, existing customer base and technology we now have access to; we plan to immediately roll out several new hemp and CBD initiatives.
* "Our goal has always been to control every step of the production process from genetics, right through to extraction, ensuring only the highest quality extracts are used in the formulation of our strips, time release capsules and other products currently under development for the medical and recreational cannabis space,"
About MJ Biopharma
MJ Biopharma is a cannabis technology company with a team of highly experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:
Manufacturing breath strips;
Time release capsules;
Extract oils;
Food products and infused juices, teas, coffee and extract drinks;
Pharmaceutical grade delivery systems;
This is a massive operation !! Look at Facility in Europe below.
Major LP's will want to partner with us or just take us out ...They want the European market !
Facility video 1
Facility video 2
Picture
VIN NUMBERS: audited annual sales in excess of CAD $14,000,000 and adjusted EBITDA of over $2,000,000
vs
Canopy Growth Numbers
Do the math people...VNNYF is a target for the big boyz, who will act 1st...?
Access to an extensive catalogue of over 2000 hemp and cannabis strains
I don't think people understand the value of those strains with IP (Intellectual Property) But the big players will....
VNNYF (MJ BIOPHARMA) PLAN:
* Expand rapidly into the hemp, cannabis and cannabinoid (CBD) sectors across Europe.
* Utilize our first mover advantage to take a leading market position in multiple countries
* "Given the current marketplace dynamics, existing customer base and technology we now have access to; we plan to immediately roll out several new hemp and CBD initiatives.
* "Our goal has always been to control every step of the production process from genetics, right through to extraction, ensuring only the highest quality extracts are used in the formulation of our strips, time release capsules and other products currently under development for the medical and recreational cannabis space,"
* The Company will aim to work with large growers and provide access for them to a comprehensive catalogue of cannabis strains.
* MJ Biopharma's expertise lies in its extracts and custom formulations. The company will also aim to in- license and joint venture on best in class technologies and products for both the medicinal and recreational markets - domestically and internationally.
About MJ Biopharma
MJ Biopharma is a cannabis technology company with a team of highly experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:
Manufacturing breath strips;
Time release capsules;
Extract oils;
Food products and infused juices, teas, coffee and extract drinks;
Pharmaceutical grade delivery systems;
MJ BIOPHARMA
No dilution here, 36m market cap, and very very tight float...under 15million free trading imo...
I see $3 short term here. Then $4-5
From the very respected Technical420.com:
Becoming a Global Cannabis Opportunity
When the market starts catching on watch out....
Look at AXIM Biotechologies,
Oct 24tgh 2016 AXIM was trading at 40 cents....3 montsh later Jan 12th 2017, $19.80
They are in the cannabinoid delivery system (As is VNNYF)...
AXIM 700 Million market cap, They make no money and have no money:
Earning a current market cap value of $772M, AXIM has $870k in cash on the books, which stands against about $4.1M total current liabilities. AXIM is effectively pre-revenue at this point.
About AXIM
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products.
AXIM Biotechnologies Inc. has made a name for itself by creating unique delivery systems for cannabinoids
Now VNNYF, 40 million market cap, with this deal already makes 14million x 51%.
Specializing in pharmaceutical grade delivery platforms, the company believes it can deliver CBD therapies better, faster, and more effectively than others
In chatting to the company’s team, they made clear that they see themselves as less a cannabis company than a biopharma play, wherein they’ll be working on formulations that other companies can’t replicate, using delivery systems both established and innovative, such as breath strips, oils, sprays, and time release pills.
Here the latest from Chris Parry:
Source Here
Vinergy Resources (VIN.C) buys their own ‘green organic Dutchman
New cannabis player Vinergy Resources (VIN.C) has announced a surprise deal to acquire a potential 51% stake in an established a European growhouse, nursery, and tissue culture player with decades of history in the business.
The target company that already does $14 million annually in audited revenue selling plants across Europe and beyond, is looking to expand into marijuana cultivation to fill a fast growing demand in nations such as Germany and Switzerland.
The company has shipped 35 million indoor, outdoor and edible plants globally from its lab and nursery headquarters.
Vinergy is a recent entrant into the Canadian public company cannabis space, with some of the technology coming from a family-owned, hard science background lab, while this latest acquisition is an established, mass agriculture business that currently sends indoor and outdoor plants to customers around the world, with a thriving tissue culture business already in operation within the potato trade.
The deal is a concerted push into the international space for Vinergy, where it sees long term growth potential in both the agricultural space in general, and more specifically across the cannabis sector.
Stock in VIN.C jumped 21% on the news, from $0.89 to $1.03.
The company share price has been on a tear of late, running from $0.10 on December 6 to $0.50 a month later, and now hitting ten-bagger territory.
The company they’re buying into has an FDA-certified laboratory with a R&D facility, rooting station, and weening facilities in in addition to a low cost, high efficiency lab.
The target’s plan is to make a global push into the tissue culturing industry, where it sees much potential in a business currently served by third world players developing low grade products. To that end, it began operations in the potato industry, using tissue culturing to cut turnaround time for crops by as much as 2/3.
Currently, the company does 65% (€ 6.2 million annually) of its business in indoor plants, 20% in outdoors plants, and 15% in seed potatoes through its tissue culturing set-up.
Existing and potential customers include large retail players such as Home Depot, Wal-Mart, Costco, and similar sized European chains, as well as large scale agricultural operations.
The marijuana push within the company comes with an existing cannabis license, an export license, and strong interest from the growing EU market for cannabis and CBDs. Money from the sale to Vinergy will reportedly go towards building out that aspect of the business and accelerating the cannabis product development side.
For Vinergy, the deal looks easy to finance, given current market conditions, and opens a significant market to their products, licensing deals, and technology. At worst, they’re paying for a successful agricultural set-up that has market share, revenue, and is profitable. At best, they get to turn on the weed side of the business, while the tissue culturing operation shifts gears into the cannabis market, bringing a high ceiling of potential revenues going forward. The opportunity to move their own products into Europe through an existing supply chain is a big deal.
Vinergy recently announced it had commenced trading on the OTCQB.
I love this older Chris Parry article from 1 month ago (Jan 18) He's calling VNNYF the GW Pharma (GWPH) in the making:
Source here
Vinergy Resources/MJ Biopharma (VIN.C) ramps up to clinical testing of CBD therapeutics
Vinergy Resources (VIN.C) may still sound like a mining company, but the innovative CBD product development house acquiring MJ Biopharma is neck deep in its push toward establishing legit clinical trials for cannabidiol-related therapeutics.
The GW Pharma-in-the-making announced Wednesday it had signed Dr. William Panenka, MD, as the Chair of its Scientific Advisory Board, a move that establishes the credentials of the company in chasing a Big Pharma future for its products.
Panenka is one of only two specialists in Western Canada that has dual certification from the College of Physicians and Surgeons of Canada in neurology and psychiatry.
Panenka collaborates on multiple studies in brain issues, such as the multi-departmental 10-year study in Vancouver’s poorest neighbourhood to do cognitive phenotyping, neurophyschiatric assessments, and multimodal MRI on drug addicted and mental health patients. He is also the medical lead in BC’s largest concussion clinic, and is part of a multidisciplinary team at UBC neuropsychiatry, and the BC Primary Site Investigator, on a national study for Brain Canada following TBI patients.
In layman’s terms: Panenka is one smart dude, and if you’re looking to develop CBD treatments for PTSD, concussions, mental health issues, addiction, and anything that relates to the brain, he’s the kind of guy who can direct your study and help you work through Health Canada approvals.
Also worth noting: Dr. Panenka is part of a team that was recently awarded a MITACS UBC industry grant to study the pharmacodynamics and pharmacokinetics of cannabis absorption in pre-clinical models, as well as test the effects of various cultivars for their effect on anxiety and pain.
Vinergy will be a new play to a lot of people, having just recently appeared after a $2 million raise, but the playbook for this company is as follows:
The technology came out of an established lab that does contract development work for mid and large companies in the biotech space, which saw an opportunity in the cannabis arena to implement some of their IP and expertise in new ways.
Specializing in pharmaceutical grade delivery platforms, the company believes it can deliver CBD therapies better, faster, and more effectively than others.
Product focus will initially be breath strips, time release capsules, and infused food products
The company announced the acquisition in December last year, and between January 6 and the time of writing, as climbed from $0.43 to $0.69 with high volume.
In chatting to the company’s team, they made clear that they see themselves as less a cannabis company than a biopharma play, wherein they’ll be working on formulations that other companies can’t replicate, using delivery systems both established and innovative, such as breath strips, oils, sprays, and time release pills.
I got a call last night from a well-heeled investor who is often at the forefront of new sector movements, and he asked me some pointed question about CBD pharmaceutical plays and whether I think they’re the next big thing.
To be clear: I do.
If the multi-billion dollar success of GW Pharma (GWPH: NASDAQ) has shown us anything, it’s that the coiled potential of the green rush doesn’t come down to who’s growing the raw materials, it comes down to what you do with them, and how well you can take them into the mainstream as a legitimate, easy to use, effective and clinically trialed medicine.
While information on Vinergy’s plans in this respect is in short supply just now, investors are clearly getting in front of the news, and today’s hiring notice will confirm the seriousness with which the organization is moving forward.
— Chris Parry
20x ($14m x 51%) = $140 million = $3.88
Using 25:
25x (414m x 51%) = $178 million = $4.44
$3+ coming, Here's why....
Note ** This is all based on just this 1 current deal:
Annual sales in excess of CAD $14,000,000 and adjusted EBITDA of over CAD $2,000,000
LP's in Canada are currently valued at 20-25 times revenue
Using 20:
20x ($14m x 51%) = $140 million
Using 25:
25x (414m x 51%) = $178 million
Thus at 36m shares VIN should be trading north of $3 once the deal closes.
Again i just used current acquisition historical sales
* Other deals could happen
* VIN is looking to go global
* VIN is looking to work with large growers and provide access for them to a comprehensive catalogue of cannabis strains.
* The company will also aim to in- license and joint venture on best in class technologies and products for both the medicinal and recreational markets - domestically and internationally.
So honestly....$3 is the bare minimum for VIN...
And who knows...one of the big 5 (WEED, APH, ACB, OGI, EMC) could be interested in our internatioal oil patent and now, 2000 IP canabis strains and Euro / Global market reach...
This is a massive operation !! Look at Facility in Europe.
Major LP's will want this...They want the European market !
Facility Video 1
Facility Video 2
VIN NUMBERS: audited annual sales in excess of CAD $14,000,000 and adjusted EBITDA of over $2,000,000
CANOPY GROWTH NUMBERS
Do the math people...VNNYF i snow a target for the big noyz, who will act 1st...?
MarijuanaStocks,com Biotech update !!
http://marijuanastocks.com/biotech-update/
THE VIN (MJ BIOPHARMA) PLAN
Again,
Audited annual sales in excess of CAD $14,000,000 and adjusted EBITDA of over CAD $2,000,000.
Access to an extensive catalogue of over 2000 hemp and cannabis strains
I don't think people understand the value of those strains with IP (Intellectual Property) But the big players will....
VIN (MJ BIOPHARMA) PLAN:
* Expand rapidly into the hemp, cannabis and cannabinoid (CBD) sectors across Europe.
* Utilize our first mover advantage to take a leading market position in multiple countries
* "Given the current marketplace dynamics, existing customer base and technology we now have access to; we plan to immediately roll out several new hemp and CBD initiatives.
* "Our goal has always been to control every step of the production process from genetics, right through to extraction, ensuring only the highest quality extracts are used in the formulation of our strips, time release capsules and other products currently under development for the medical and recreational cannabis space,"
* The Company will aim to work with large growers and provide access for them to a comprehensive catalogue of cannabis strains.
* MJ Biopharma's expertise lies in its extracts and custom formulations. The company will also aim to in- license and joint venture on best in class technologies and products for both the medicinal and recreational markets - domestically and internationally.
About MJ Biopharma
MJ Biopharma is a cannabis technology company with a team of highly experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:
Manufacturing breath strips;
Time release capsules;
Extract oils;
Food products and infused juices, teas, coffee and extract drinks;
Pharmaceutical grade delivery systems;
This morning, Vinergy “MJ Biopharma” (CSE: VIN & OTCQB:VNNYF) announced that it has signed on LOI to Acquire a Majority Stake in a Multinational Plant Breeder with $14M in Annual Sales & an EBITDA of over $2M
News Key highlights:
1) Today’s news release comes after the company announced the commencement of shares trading on the OTCQB Venture Marketplace under the symbol VNNYF. Thus allowing for increased accessibility and visibility with U.S. investors.
2) This morning the company officially announces their entry in the global cannabis industry as a major diversified player with Global reach. As well it positions them as one of highest revenue generating companies in this space. This deal will also make Vinergy is amongst the most profitable companies in the Cannabis industry. Similar Canadian comparables are trading at several multiples of their future revenues.
3) The Deal:
- The LOI is for a majority stake (51%) in a European multinational plant breeder.
- The deal is expected to close in tranches, with the first being in Q1-2017.
4) The Target company:
- The target is a European multinational Company.
- With audited annual sales in excess of CAD $14M and EBITDA of over $2M.
- A world leader in the development of plants and plant genetics.
- Has a long established history and has been providing commercial agriculture services for over 25 years to global customers.
- In the past year alone, they shipped over 35M plant products internationally.
5) Strategic Plan and Synergy
- This transaction fits perfectly with the direction VIN is pursuing.
o On Jan 18, 2017, VIN announced the appointment of a Scientific Advisory Board Chair to Pursue Clinical Testing of Cannabinoids for Therapeutics and emphasized that it is an important part of the Company’s strategy to develop, test and identify specific cannabinoid isolates for targeted therapeutic purposes.
- Together with VIN, the Target currently has the capacity to expand rapidly into the hemp, cannabis and cannabinoid (CBD) sectors across Europe.
o Europe’s market potential for CBD is estimated to be €2 billion.
o The total U.S. CBD market is estimated to grow to a $2.1 billion market in consumer sales by 2020.
- As part of the acquisition, VIN now has access to an extensive catalogue of over 2000 hemp and cannabis strains with the ability to supply those strains to customers globally.
6) Plan Forward
- VIN’s goal is to control every step of the production process, from genetics, right through to extraction, ensuring only the highest quality extracts are used in the formulation of their products (strips, time release capsules and other products currently under development for the medical and recreational cannabis space)
- VIN has stated that, with this acquisition, they plan to immediately roll out several new hemp and CBD initiatives.
- With a main goal of taking a leading market position in the global CBD market, VIN will remain diversified and will capitalize on and further develop the multiple complimentary and recurring revenue streams already established by the target company.
- VIN will aim to work with large growers to gain access to multiple markets and distribution verticals worldwide, thus ensuring that VIN will work towards being the supplier of choice for companies seeking access to the largest and finest catalogue of cannabis strains globally.
Link to news: http://www.marketwired.com/press-release/vinergy-resources-mj-biopharma-acquire-majority-stake-multinational-plant-breeder-with-cse-vin-2192979.htm